Tageos and Wiliot Partner to Accelerate Ambient IoT, Battery-Free BLE Sensing
22.1.2026 16:07:00 CET | Business Wire | Press Release
Tageos, a global leader in RFID and wireless IoT inlays and tags, today announced a strategic partnership with ambient IoT pioneer Wiliot. The first outcome of this collaboration is the launch of a new passive Bluetooth® Low Energy (BLE) inlay, the EOS-654 BLE G3. In response growing demand for real-time location and condition monitoring across retail and logistics supply chains, this inlay was developed to support large-scale deployment of Wiliot’s Gen3 IoT Pixel sensor and the Wiliot Intelligence Platform.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260122940104/en/
The new EOS-654 BLE G3 features a dual-band architecture operating at 2.4 GHz and sub-1 GHz. This inlay design enables longer-range energizing, more reliable broadcasts, and greater performance consistency across environments such as distribution centers, trailers, retail backrooms, and store floors. Delivered as a dry inlay, it is ready for conversion into Wiliot’s Gen3 IoT Pixel sensor.
Requiring no batteries, the Gen3 IoT Pixel sensor works with cost-effective Bluetooth reader infrastructure to transmit item-level data to the Wiliot Intelligence Platform. The platform analyzes continuous streams of location, temperature, humidity, light, dwell time, and movement data to power physical AI solutions, including cycle counting, shipment verification, reusable asset tracking, and condition monitoring.
The EOS-654 BLE G3 inlay was developed in cooperation with Wiliot at Tageos’ Innovation Center of Excellence (ICoE), which opened in Munich, Germany, in April 2025 in response to increasing demand for cutting-edge wireless technologies. Specializing in product innovations such as advanced antenna design, battery-free and battery-powered BLE sensors, and multi-component integration into roll-to-roll inlay manufacturing, the ICoE is part of the company’s comprehensive research and development organization. Once final product development and validation are complete, products can be seamlessly industrialized within Tageos’ global manufacturing network, which currently has a total production capacity of 12 billion units per year across locations in France, the United States, and China.
“We are proud to work with a global, high-capacity inlay manufacturer to further secure supply for the growing demand for our battery-free Gen3 IoT Pixel BLE sensors,” said Amir Khoshniyati, VP Marketing and Business Development at Wiliot. “Combined with the Wiliot Intelligence Platform, this partnership powers the data layer behind physical AI and redefines real-time visibility across modern supply chains. Tageos’ innovation capabilities and proven ability to scale to billions of units make them an ideal partner for our rapid growth in ambient IoT.”
“With Tageos’ innovation and commitment to quality, in addition to our expertise in inlay manufacturing, combined with our capacity we are taking another significant step towards ambient IoT performance and battery-free BLE sensing technology,” said Hector Gomez, VP of Specialty Products at Tageos. “Wiliot shares our commitment to pioneering ideas and actions, and we are excited to expand our partnership further to unlock new applications and drive ongoing growth for the benefit of our customers worldwide.”
###
About Tageos
Tageos® is a global market leader in the design and manufacturing of RFID and wireless IoT inlays and tags. We provide a comprehensive portfolio of high-quality, innovative products and sensors (RAIN RFID/UHF, NFC/HF, BLE), enabling end-customers such as retailers, brand owners, and industrial manufacturers to identify, authenticate, track, and trace a wide range of products and assets. Tageos is ISO 9001:2015 and ISO 14001:2015 certified and holds ARC Quality Certification from Auburn University’s RFID Lab. Headquartered in Montpellier, France, Tageos operates manufacturing sites and offices in France, USA, China, Germany, Hong Kong (SAR), Italy, and Mexico.
About Wiliot
Wiliot, a pioneer of Ambient IoT, powers your supply chain with continuous, scan-free visibility into item location and condition. The Wiliot Intelligence Platform processes signals from battery-free Bluetooth sensors (IoT Pixels) in the Wiliot Cloud using purpose-built AI and ML models. This enables real-time automated condition monitoring, inventory intelligence, and workflow optimization. Whether you have AI in place or are just starting, Wiliot delivers continuous, AI-ready data that drives ROI today and scales into advanced AI tomorrow.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260122940104/en/
Contacts
Media Inquiries:
Geoffrey Riggs
Global Communications Manager
communications@tageos.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 14:00:00 CEST | Press Release
Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP alone as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. The oral presentation of these data is taking place at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting being held May 29 – June 2, 2026, in Chicago (Abstract #LBA7000. Session: Oral Abstract Session – Hematologic Malignancies – Lymphoma and Chronic Lymphocytic Leukemia. May 30, 4:00 – 7:00 p.m. ET [3:00 – 6:00 p.m.
Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press Release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press Release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press Release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press Release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom